Tandem Diabetes Care, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (TNDM). Impacted investors are advised to contact the firm now.

The investigation focuses on whether Tandem Diabetes Care made false or misleading statements and/or omitted material information regarding the safety and reliability of its t:slim X2 insulin pumps. On August 7, 2025, Tandem Diabetes Care announced a “voluntary medical device correction” for the t:slim X2 insulin pumps due to a speaker-related defect that could stop insulin delivery and disrupt communication with continuous glucose monitoring devices. The Company disclosed that this malfunction, known as “Malfunction 16,” had resulted in 700 confirmed adverse events and 59 reported injuries.

On this news, Tandem Diabetes Care's stock price fell $2.87 per share, or 19.9%, to close at $11.53 on Aug. 7, 2025.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.